BTIG analyst Ryan Zimmerman has maintained their neutral stance on HOLX stock, giving a Hold rating on September 18.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ryan Zimmerman has given his Hold rating due to a combination of factors influencing Hologic’s future performance. The company is expected to experience an acceleration in growth by FY26, transitioning into what Zimmerman describes as an ‘accelerating growth story.’ However, this growth is projected from a relatively low base, and there are uncertainties regarding the company’s ability to sustain a 5% or more top-line growth by FY27, which is crucial for achieving double-digit EPS growth.
Despite potential improvements in EPS growth, especially in the latter half of FY26, Hologic faces transient headwinds that could limit its growth cadence in FY25 and FY26. The stock is currently trading at a discount compared to its peers, with limited opportunities for multiple expansion given the current growth rates. Therefore, Zimmerman maintains a Neutral stance, suggesting that while there is potential for growth, the upside is limited under current conditions.
In another report released on September 18, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $72.00 price target.